nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—Ritonavir—acquired immunodeficiency syndrome	0.284	0.551	CrCtD
Carfilzomib—Lopinavir—acquired immunodeficiency syndrome	0.231	0.449	CrCtD
Carfilzomib—Ritonavir—Lopinavir—acquired immunodeficiency syndrome	0.0963	0.317	CrCrCtD
Carfilzomib—Lopinavir—Ritonavir—acquired immunodeficiency syndrome	0.0785	0.258	CrCrCtD
Carfilzomib—Lopinavir—Indinavir—acquired immunodeficiency syndrome	0.0699	0.23	CrCrCtD
Carfilzomib—Lopinavir—Saquinavir—acquired immunodeficiency syndrome	0.0595	0.196	CrCrCtD
Carfilzomib—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0136	0.167	CbGbCtD
Carfilzomib—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0123	0.151	CbGbCtD
Carfilzomib—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0106	0.131	CbGbCtD
Carfilzomib—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0103	0.127	CbGbCtD
Carfilzomib—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.00929	0.115	CbGbCtD
Carfilzomib—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.00929	0.115	CbGbCtD
Carfilzomib—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00891	0.11	CbGbCtD
Carfilzomib—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00689	0.085	CbGbCtD
Carfilzomib—PSMB10—lymphoid tissue—acquired immunodeficiency syndrome	0.00104	0.041	CbGeAlD
Carfilzomib—PSMB10—digestive system—acquired immunodeficiency syndrome	0.00102	0.0405	CbGeAlD
Carfilzomib—PSMB10—blood—acquired immunodeficiency syndrome	0.000976	0.0385	CbGeAlD
Carfilzomib—PSMB10—lung—acquired immunodeficiency syndrome	0.000856	0.0338	CbGeAlD
Carfilzomib—PSMB10—nervous system—acquired immunodeficiency syndrome	0.000793	0.0313	CbGeAlD
Carfilzomib—PSMB10—central nervous system—acquired immunodeficiency syndrome	0.000763	0.0301	CbGeAlD
Carfilzomib—PSMB2—retina—acquired immunodeficiency syndrome	0.000708	0.028	CbGeAlD
Carfilzomib—PSMB1—skin of body—acquired immunodeficiency syndrome	0.000637	0.0252	CbGeAlD
Carfilzomib—PSMB8—blood—acquired immunodeficiency syndrome	0.000629	0.0248	CbGeAlD
Carfilzomib—PSMB2—skin of body—acquired immunodeficiency syndrome	0.000622	0.0245	CbGeAlD
Carfilzomib—PSMB8—bone marrow—acquired immunodeficiency syndrome	0.000609	0.024	CbGeAlD
Carfilzomib—PSMB10—brain—acquired immunodeficiency syndrome	0.000606	0.0239	CbGeAlD
Carfilzomib—PSMB10—lymph node—acquired immunodeficiency syndrome	0.000585	0.0231	CbGeAlD
Carfilzomib—PSMB8—vagina—acquired immunodeficiency syndrome	0.000583	0.023	CbGeAlD
Carfilzomib—PSMB5—blood—acquired immunodeficiency syndrome	0.000556	0.0219	CbGeAlD
Carfilzomib—PSMB8—lung—acquired immunodeficiency syndrome	0.000551	0.0218	CbGeAlD
Carfilzomib—PSMB5—bone marrow—acquired immunodeficiency syndrome	0.000538	0.0212	CbGeAlD
Carfilzomib—PSMB5—spinal cord—acquired immunodeficiency syndrome	0.000535	0.0211	CbGeAlD
Carfilzomib—PSMB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000516	0.0204	CbGeAlD
Carfilzomib—PSMB5—vagina—acquired immunodeficiency syndrome	0.000515	0.0203	CbGeAlD
Carfilzomib—PSMB1—digestive system—acquired immunodeficiency syndrome	0.00051	0.0201	CbGeAlD
Carfilzomib—PSMB2—lymphoid tissue—acquired immunodeficiency syndrome	0.000504	0.0199	CbGeAlD
Carfilzomib—PSMB2—digestive system—acquired immunodeficiency syndrome	0.000497	0.0196	CbGeAlD
Carfilzomib—PSMB5—lung—acquired immunodeficiency syndrome	0.000487	0.0192	CbGeAlD
Carfilzomib—PSMB1—blood—acquired immunodeficiency syndrome	0.000486	0.0192	CbGeAlD
Carfilzomib—PSMB2—blood—acquired immunodeficiency syndrome	0.000474	0.0187	CbGeAlD
Carfilzomib—PSMB1—bone marrow—acquired immunodeficiency syndrome	0.00047	0.0186	CbGeAlD
Carfilzomib—PSMB1—spinal cord—acquired immunodeficiency syndrome	0.000468	0.0185	CbGeAlD
Carfilzomib—PSMB2—bone marrow—acquired immunodeficiency syndrome	0.000459	0.0181	CbGeAlD
Carfilzomib—PSMB2—spinal cord—acquired immunodeficiency syndrome	0.000457	0.018	CbGeAlD
Carfilzomib—PSMB1—vagina—acquired immunodeficiency syndrome	0.00045	0.0178	CbGeAlD
Carfilzomib—PSMB2—vagina—acquired immunodeficiency syndrome	0.000439	0.0173	CbGeAlD
Carfilzomib—PSMB1—lung—acquired immunodeficiency syndrome	0.000426	0.0168	CbGeAlD
Carfilzomib—PSMB2—lung—acquired immunodeficiency syndrome	0.000415	0.0164	CbGeAlD
Carfilzomib—PSMB1—nervous system—acquired immunodeficiency syndrome	0.000394	0.0156	CbGeAlD
Carfilzomib—PSMB8—brain—acquired immunodeficiency syndrome	0.00039	0.0154	CbGeAlD
Carfilzomib—PSMB2—nervous system—acquired immunodeficiency syndrome	0.000385	0.0152	CbGeAlD
Carfilzomib—PSMB1—central nervous system—acquired immunodeficiency syndrome	0.00038	0.015	CbGeAlD
Carfilzomib—PSMB8—lymph node—acquired immunodeficiency syndrome	0.000377	0.0149	CbGeAlD
Carfilzomib—PSMB2—central nervous system—acquired immunodeficiency syndrome	0.00037	0.0146	CbGeAlD
Carfilzomib—PSMB5—brain—acquired immunodeficiency syndrome	0.000345	0.0136	CbGeAlD
Carfilzomib—PSMB5—lymph node—acquired immunodeficiency syndrome	0.000333	0.0132	CbGeAlD
Carfilzomib—PSMB1—brain—acquired immunodeficiency syndrome	0.000301	0.0119	CbGeAlD
Carfilzomib—PSMB2—brain—acquired immunodeficiency syndrome	0.000294	0.0116	CbGeAlD
Carfilzomib—PSMB1—lymph node—acquired immunodeficiency syndrome	0.000291	0.0115	CbGeAlD
Carfilzomib—PSMB2—lymph node—acquired immunodeficiency syndrome	0.000284	0.0112	CbGeAlD
Carfilzomib—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000198	0.0078	CbGeAlD
Carfilzomib—Back pain—Zidovudine—acquired immunodeficiency syndrome	0.000128	0.00255	CcSEcCtD
Carfilzomib—Arthralgia—Abacavir—acquired immunodeficiency syndrome	0.000127	0.00255	CcSEcCtD
Carfilzomib—Pneumonia—Saquinavir—acquired immunodeficiency syndrome	0.000127	0.00254	CcSEcCtD
Carfilzomib—Muscle spasms—Zidovudine—acquired immunodeficiency syndrome	0.000127	0.00254	CcSEcCtD
Carfilzomib—Hypoaesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000127	0.00254	CcSEcCtD
Carfilzomib—Chills—Indinavir—acquired immunodeficiency syndrome	0.000127	0.00253	CcSEcCtD
Carfilzomib—Neutropenia—Lamivudine—acquired immunodeficiency syndrome	0.000126	0.00253	CcSEcCtD
Carfilzomib—Thrombocytopenia—Nevirapine—acquired immunodeficiency syndrome	0.000126	0.00251	CcSEcCtD
Carfilzomib—Oedema peripheral—Delavirdine—acquired immunodeficiency syndrome	0.000126	0.00251	CcSEcCtD
Carfilzomib—Renal failure—Saquinavir—acquired immunodeficiency syndrome	0.000124	0.00248	CcSEcCtD
Carfilzomib—Decreased appetite—Didanosine—acquired immunodeficiency syndrome	0.000124	0.00248	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Saquinavir—acquired immunodeficiency syndrome	0.000124	0.00248	CcSEcCtD
Carfilzomib—Cardiac disorder—Efavirenz—acquired immunodeficiency syndrome	0.000124	0.00247	CcSEcCtD
Carfilzomib—Anorexia—Nevirapine—acquired immunodeficiency syndrome	0.000122	0.00245	CcSEcCtD
Carfilzomib—Pain—Didanosine—acquired immunodeficiency syndrome	0.000122	0.00244	CcSEcCtD
Carfilzomib—Anaemia—Zidovudine—acquired immunodeficiency syndrome	0.000122	0.00244	CcSEcCtD
Carfilzomib—Hyperglycaemia—Lamivudine—acquired immunodeficiency syndrome	0.000122	0.00244	CcSEcCtD
Carfilzomib—Thrombocytopenia—Nelfinavir—acquired immunodeficiency syndrome	0.000122	0.00243	CcSEcCtD
Carfilzomib—Thrombocytopenia—Stavudine—acquired immunodeficiency syndrome	0.000121	0.00243	CcSEcCtD
Carfilzomib—Infection—Abacavir—acquired immunodeficiency syndrome	0.000121	0.00243	CcSEcCtD
Carfilzomib—Thrombocytopenia—Abacavir—acquired immunodeficiency syndrome	0.00012	0.00239	CcSEcCtD
Carfilzomib—Back pain—Indinavir—acquired immunodeficiency syndrome	0.000119	0.00237	CcSEcCtD
Carfilzomib—Renal failure—Lamivudine—acquired immunodeficiency syndrome	0.000119	0.00237	CcSEcCtD
Carfilzomib—Anorexia—Nelfinavir—acquired immunodeficiency syndrome	0.000119	0.00237	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Lamivudine—acquired immunodeficiency syndrome	0.000118	0.00236	CcSEcCtD
Carfilzomib—Leukopenia—Zidovudine—acquired immunodeficiency syndrome	0.000118	0.00236	CcSEcCtD
Carfilzomib—Anorexia—Stavudine—acquired immunodeficiency syndrome	0.000118	0.00236	CcSEcCtD
Carfilzomib—Muscle spasms—Indinavir—acquired immunodeficiency syndrome	0.000118	0.00236	CcSEcCtD
Carfilzomib—Hypoaesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000117	0.00235	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Nevirapine—acquired immunodeficiency syndrome	0.000117	0.00234	CcSEcCtD
Carfilzomib—Anorexia—Abacavir—acquired immunodeficiency syndrome	0.000116	0.00233	CcSEcCtD
Carfilzomib—Oedema peripheral—Ritonavir—acquired immunodeficiency syndrome	0.000116	0.00232	CcSEcCtD
Carfilzomib—Cough—Zidovudine—acquired immunodeficiency syndrome	0.000115	0.0023	CcSEcCtD
Carfilzomib—Chills—Delavirdine—acquired immunodeficiency syndrome	0.000114	0.00229	CcSEcCtD
Carfilzomib—Anaemia—Indinavir—acquired immunodeficiency syndrome	0.000113	0.00227	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Nelfinavir—acquired immunodeficiency syndrome	0.000113	0.00226	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Stavudine—acquired immunodeficiency syndrome	0.000113	0.00226	CcSEcCtD
Carfilzomib—Hypoaesthesia—Saquinavir—acquired immunodeficiency syndrome	0.000113	0.00226	CcSEcCtD
Carfilzomib—Body temperature increased—Didanosine—acquired immunodeficiency syndrome	0.000113	0.00226	CcSEcCtD
Carfilzomib—Insomnia—Nelfinavir—acquired immunodeficiency syndrome	0.000112	0.00225	CcSEcCtD
Carfilzomib—Arthralgia—Zidovudine—acquired immunodeficiency syndrome	0.000112	0.00225	CcSEcCtD
Carfilzomib—Asthenia—Amprenavir—acquired immunodeficiency syndrome	0.000112	0.00225	CcSEcCtD
Carfilzomib—Back pain—Efavirenz—acquired immunodeficiency syndrome	0.000112	0.00224	CcSEcCtD
Carfilzomib—Insomnia—Stavudine—acquired immunodeficiency syndrome	0.000112	0.00224	CcSEcCtD
Carfilzomib—Decreased appetite—Nevirapine—acquired immunodeficiency syndrome	0.000112	0.00223	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Abacavir—acquired immunodeficiency syndrome	0.000111	0.00222	CcSEcCtD
Carfilzomib—Dyspnoea—Nelfinavir—acquired immunodeficiency syndrome	0.000111	0.00222	CcSEcCtD
Carfilzomib—Fatigue—Nevirapine—acquired immunodeficiency syndrome	0.000111	0.00221	CcSEcCtD
Carfilzomib—Insomnia—Abacavir—acquired immunodeficiency syndrome	0.00011	0.00221	CcSEcCtD
Carfilzomib—Pain—Nevirapine—acquired immunodeficiency syndrome	0.00011	0.00219	CcSEcCtD
Carfilzomib—Cardiac disorder—Ritonavir—acquired immunodeficiency syndrome	0.000109	0.00219	CcSEcCtD
Carfilzomib—Dyspnoea—Abacavir—acquired immunodeficiency syndrome	0.000109	0.00218	CcSEcCtD
Carfilzomib—ABCB1—retina—acquired immunodeficiency syndrome	0.000108	0.00427	CbGeAlD
Carfilzomib—Decreased appetite—Nelfinavir—acquired immunodeficiency syndrome	0.000108	0.00216	CcSEcCtD
Carfilzomib—Decreased appetite—Stavudine—acquired immunodeficiency syndrome	0.000108	0.00215	CcSEcCtD
Carfilzomib—Hypoaesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000108	0.00215	CcSEcCtD
Carfilzomib—Back pain—Delavirdine—acquired immunodeficiency syndrome	0.000107	0.00215	CcSEcCtD
Carfilzomib—Anaemia—Efavirenz—acquired immunodeficiency syndrome	0.000107	0.00214	CcSEcCtD
Carfilzomib—Diarrhoea—Amprenavir—acquired immunodeficiency syndrome	0.000107	0.00214	CcSEcCtD
Carfilzomib—Cough—Indinavir—acquired immunodeficiency syndrome	0.000107	0.00214	CcSEcCtD
Carfilzomib—Fatigue—Stavudine—acquired immunodeficiency syndrome	0.000107	0.00214	CcSEcCtD
Carfilzomib—Muscle spasms—Delavirdine—acquired immunodeficiency syndrome	0.000107	0.00213	CcSEcCtD
Carfilzomib—Pain—Nelfinavir—acquired immunodeficiency syndrome	0.000106	0.00213	CcSEcCtD
Carfilzomib—Decreased appetite—Abacavir—acquired immunodeficiency syndrome	0.000106	0.00212	CcSEcCtD
Carfilzomib—Pain—Stavudine—acquired immunodeficiency syndrome	0.000106	0.00212	CcSEcCtD
Carfilzomib—Constipation—Stavudine—acquired immunodeficiency syndrome	0.000106	0.00212	CcSEcCtD
Carfilzomib—Chills—Ritonavir—acquired immunodeficiency syndrome	0.000106	0.00211	CcSEcCtD
Carfilzomib—Thrombocytopenia—Zidovudine—acquired immunodeficiency syndrome	0.000105	0.00211	CcSEcCtD
Carfilzomib—Cardiac disorder—Saquinavir—acquired immunodeficiency syndrome	0.000105	0.00211	CcSEcCtD
Carfilzomib—Fatigue—Abacavir—acquired immunodeficiency syndrome	0.000105	0.0021	CcSEcCtD
Carfilzomib—Arthralgia—Indinavir—acquired immunodeficiency syndrome	0.000105	0.00209	CcSEcCtD
Carfilzomib—Pain—Abacavir—acquired immunodeficiency syndrome	0.000104	0.00209	CcSEcCtD
Carfilzomib—Anorexia—Zidovudine—acquired immunodeficiency syndrome	0.000103	0.00205	CcSEcCtD
Carfilzomib—Anaemia—Delavirdine—acquired immunodeficiency syndrome	0.000103	0.00205	CcSEcCtD
Carfilzomib—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.000102	0.00205	CcSEcCtD
Carfilzomib—Chills—Saquinavir—acquired immunodeficiency syndrome	0.000102	0.00204	CcSEcCtD
Carfilzomib—Body temperature increased—Nevirapine—acquired immunodeficiency syndrome	0.000101	0.00203	CcSEcCtD
Carfilzomib—Cough—Efavirenz—acquired immunodeficiency syndrome	0.000101	0.00202	CcSEcCtD
Carfilzomib—Hypertension—Efavirenz—acquired immunodeficiency syndrome	0.0001	0.002	CcSEcCtD
Carfilzomib—Vomiting—Amprenavir—acquired immunodeficiency syndrome	9.96e-05	0.00199	CcSEcCtD
Carfilzomib—Leukopenia—Delavirdine—acquired immunodeficiency syndrome	9.93e-05	0.00199	CcSEcCtD
Carfilzomib—Back pain—Ritonavir—acquired immunodeficiency syndrome	9.93e-05	0.00198	CcSEcCtD
Carfilzomib—Arthralgia—Efavirenz—acquired immunodeficiency syndrome	9.88e-05	0.00197	CcSEcCtD
Carfilzomib—Muscle spasms—Ritonavir—acquired immunodeficiency syndrome	9.87e-05	0.00197	CcSEcCtD
Carfilzomib—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	9.83e-05	0.00197	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Zidovudine—acquired immunodeficiency syndrome	9.82e-05	0.00196	CcSEcCtD
Carfilzomib—Headache—Amprenavir—acquired immunodeficiency syndrome	9.81e-05	0.00196	CcSEcCtD
Carfilzomib—Thrombocytopenia—Indinavir—acquired immunodeficiency syndrome	9.81e-05	0.00196	CcSEcCtD
Carfilzomib—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	9.8e-05	0.00196	CcSEcCtD
Carfilzomib—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	9.77e-05	0.00195	CcSEcCtD
Carfilzomib—Insomnia—Zidovudine—acquired immunodeficiency syndrome	9.74e-05	0.00195	CcSEcCtD
Carfilzomib—Chills—Lamivudine—acquired immunodeficiency syndrome	9.71e-05	0.00194	CcSEcCtD
Carfilzomib—Cough—Delavirdine—acquired immunodeficiency syndrome	9.69e-05	0.00194	CcSEcCtD
Carfilzomib—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	9.65e-05	0.00193	CcSEcCtD
Carfilzomib—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	9.61e-05	0.00192	CcSEcCtD
Carfilzomib—Hypertension—Delavirdine—acquired immunodeficiency syndrome	9.58e-05	0.00192	CcSEcCtD
Carfilzomib—Back pain—Saquinavir—acquired immunodeficiency syndrome	9.56e-05	0.00191	CcSEcCtD
Carfilzomib—Anorexia—Indinavir—acquired immunodeficiency syndrome	9.55e-05	0.00191	CcSEcCtD
Carfilzomib—Muscle spasms—Saquinavir—acquired immunodeficiency syndrome	9.5e-05	0.0019	CcSEcCtD
Carfilzomib—Anaemia—Ritonavir—acquired immunodeficiency syndrome	9.49e-05	0.0019	CcSEcCtD
Carfilzomib—Arthralgia—Delavirdine—acquired immunodeficiency syndrome	9.45e-05	0.00189	CcSEcCtD
Carfilzomib—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	9.37e-05	0.00187	CcSEcCtD
Carfilzomib—Nausea—Amprenavir—acquired immunodeficiency syndrome	9.3e-05	0.00186	CcSEcCtD
Carfilzomib—Fatigue—Zidovudine—acquired immunodeficiency syndrome	9.29e-05	0.00186	CcSEcCtD
Carfilzomib—Thrombocytopenia—Efavirenz—acquired immunodeficiency syndrome	9.27e-05	0.00185	CcSEcCtD
Carfilzomib—Pain—Zidovudine—acquired immunodeficiency syndrome	9.21e-05	0.00184	CcSEcCtD
Carfilzomib—Constipation—Zidovudine—acquired immunodeficiency syndrome	9.21e-05	0.00184	CcSEcCtD
Carfilzomib—Asthenia—Nevirapine—acquired immunodeficiency syndrome	9.21e-05	0.00184	CcSEcCtD
Carfilzomib—Leukopenia—Ritonavir—acquired immunodeficiency syndrome	9.19e-05	0.00184	CcSEcCtD
Carfilzomib—Anaemia—Saquinavir—acquired immunodeficiency syndrome	9.13e-05	0.00183	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	9.13e-05	0.00183	CcSEcCtD
Carfilzomib—Back pain—Lamivudine—acquired immunodeficiency syndrome	9.12e-05	0.00182	CcSEcCtD
Carfilzomib—Vomiting—Didanosine—acquired immunodeficiency syndrome	9.08e-05	0.00181	CcSEcCtD
Carfilzomib—Insomnia—Indinavir—acquired immunodeficiency syndrome	9.06e-05	0.00181	CcSEcCtD
Carfilzomib—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	9.06e-05	0.00181	CcSEcCtD
Carfilzomib—Anorexia—Efavirenz—acquired immunodeficiency syndrome	9.02e-05	0.0018	CcSEcCtD
Carfilzomib—Infection—Delavirdine—acquired immunodeficiency syndrome	9e-05	0.0018	CcSEcCtD
Carfilzomib—Cough—Ritonavir—acquired immunodeficiency syndrome	8.96e-05	0.00179	CcSEcCtD
Carfilzomib—Headache—Didanosine—acquired immunodeficiency syndrome	8.94e-05	0.00179	CcSEcCtD
Carfilzomib—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	8.93e-05	0.00179	CcSEcCtD
Carfilzomib—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	8.92e-05	0.00178	CcSEcCtD
Carfilzomib—Asthenia—Stavudine—acquired immunodeficiency syndrome	8.89e-05	0.00178	CcSEcCtD
Carfilzomib—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	8.87e-05	0.00177	CcSEcCtD
Carfilzomib—Hypertension—Ritonavir—acquired immunodeficiency syndrome	8.86e-05	0.00177	CcSEcCtD
Carfilzomib—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	8.84e-05	0.00177	CcSEcCtD
Carfilzomib—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	8.78e-05	0.00176	CcSEcCtD
Carfilzomib—Asthenia—Abacavir—acquired immunodeficiency syndrome	8.76e-05	0.00175	CcSEcCtD
Carfilzomib—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	8.74e-05	0.00175	CcSEcCtD
Carfilzomib—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	8.71e-05	0.00174	CcSEcCtD
Carfilzomib—Anaemia—Lamivudine—acquired immunodeficiency syndrome	8.71e-05	0.00174	CcSEcCtD
Carfilzomib—Fatigue—Indinavir—acquired immunodeficiency syndrome	8.64e-05	0.00173	CcSEcCtD
Carfilzomib—Anorexia—Delavirdine—acquired immunodeficiency syndrome	8.63e-05	0.00173	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	8.63e-05	0.00172	CcSEcCtD
Carfilzomib—Cough—Saquinavir—acquired immunodeficiency syndrome	8.62e-05	0.00172	CcSEcCtD
Carfilzomib—Constipation—Indinavir—acquired immunodeficiency syndrome	8.57e-05	0.00171	CcSEcCtD
Carfilzomib—Pain—Indinavir—acquired immunodeficiency syndrome	8.57e-05	0.00171	CcSEcCtD
Carfilzomib—Insomnia—Efavirenz—acquired immunodeficiency syndrome	8.56e-05	0.00171	CcSEcCtD
Carfilzomib—Hypertension—Saquinavir—acquired immunodeficiency syndrome	8.53e-05	0.00171	CcSEcCtD
Carfilzomib—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	8.52e-05	0.0017	CcSEcCtD
Carfilzomib—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	8.51e-05	0.0017	CcSEcCtD
Carfilzomib—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	8.48e-05	0.0017	CcSEcCtD
Carfilzomib—Nausea—Didanosine—acquired immunodeficiency syndrome	8.48e-05	0.0017	CcSEcCtD
Carfilzomib—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	8.44e-05	0.00169	CcSEcCtD
Carfilzomib—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	8.44e-05	0.00169	CcSEcCtD
Carfilzomib—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	8.41e-05	0.00168	CcSEcCtD
Carfilzomib—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	8.36e-05	0.00167	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	8.25e-05	0.00165	CcSEcCtD
Carfilzomib—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	8.23e-05	0.00165	CcSEcCtD
Carfilzomib—Cough—Lamivudine—acquired immunodeficiency syndrome	8.22e-05	0.00164	CcSEcCtD
Carfilzomib—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	8.22e-05	0.00164	CcSEcCtD
Carfilzomib—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	8.2e-05	0.00164	CcSEcCtD
Carfilzomib—Dizziness—Stavudine—acquired immunodeficiency syndrome	8.2e-05	0.00164	CcSEcCtD
Carfilzomib—Insomnia—Delavirdine—acquired immunodeficiency syndrome	8.19e-05	0.00164	CcSEcCtD
Carfilzomib—Vomiting—Nevirapine—acquired immunodeficiency syndrome	8.16e-05	0.00163	CcSEcCtD
Carfilzomib—Fatigue—Efavirenz—acquired immunodeficiency syndrome	8.16e-05	0.00163	CcSEcCtD
Carfilzomib—Pain—Efavirenz—acquired immunodeficiency syndrome	8.1e-05	0.00162	CcSEcCtD
Carfilzomib—Constipation—Efavirenz—acquired immunodeficiency syndrome	8.1e-05	0.00162	CcSEcCtD
Carfilzomib—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	8.08e-05	0.00161	CcSEcCtD
Carfilzomib—Dizziness—Abacavir—acquired immunodeficiency syndrome	8.08e-05	0.00161	CcSEcCtD
Carfilzomib—Headache—Nevirapine—acquired immunodeficiency syndrome	8.04e-05	0.00161	CcSEcCtD
Carfilzomib—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	8.02e-05	0.0016	CcSEcCtD
Carfilzomib—Infection—Saquinavir—acquired immunodeficiency syndrome	8.01e-05	0.0016	CcSEcCtD
Carfilzomib—Anorexia—Ritonavir—acquired immunodeficiency syndrome	7.98e-05	0.0016	CcSEcCtD
Carfilzomib—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	7.92e-05	0.00158	CcSEcCtD
Carfilzomib—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	7.91e-05	0.00158	CcSEcCtD
Carfilzomib—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	7.89e-05	0.00158	CcSEcCtD
Carfilzomib—Vomiting—Stavudine—acquired immunodeficiency syndrome	7.88e-05	0.00158	CcSEcCtD
Carfilzomib—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	7.87e-05	0.00157	CcSEcCtD
Carfilzomib—Fatigue—Delavirdine—acquired immunodeficiency syndrome	7.81e-05	0.00156	CcSEcCtD
Carfilzomib—Headache—Nelfinavir—acquired immunodeficiency syndrome	7.79e-05	0.00156	CcSEcCtD
Carfilzomib—Headache—Stavudine—acquired immunodeficiency syndrome	7.77e-05	0.00155	CcSEcCtD
Carfilzomib—Vomiting—Abacavir—acquired immunodeficiency syndrome	7.76e-05	0.00155	CcSEcCtD
Carfilzomib—Pain—Delavirdine—acquired immunodeficiency syndrome	7.75e-05	0.00155	CcSEcCtD
Carfilzomib—Constipation—Delavirdine—acquired immunodeficiency syndrome	7.75e-05	0.00155	CcSEcCtD
Carfilzomib—Asthenia—Zidovudine—acquired immunodeficiency syndrome	7.73e-05	0.00155	CcSEcCtD
Carfilzomib—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	7.69e-05	0.00304	CbGeAlD
Carfilzomib—Anorexia—Saquinavir—acquired immunodeficiency syndrome	7.69e-05	0.00154	CcSEcCtD
Carfilzomib—Headache—Abacavir—acquired immunodeficiency syndrome	7.65e-05	0.00153	CcSEcCtD
Carfilzomib—Infection—Lamivudine—acquired immunodeficiency syndrome	7.64e-05	0.00153	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	7.63e-05	0.00153	CcSEcCtD
Carfilzomib—Nausea—Nevirapine—acquired immunodeficiency syndrome	7.63e-05	0.00152	CcSEcCtD
Carfilzomib—ABCB1—digestive system—acquired immunodeficiency syndrome	7.6e-05	0.003	CbGeAlD
Carfilzomib—Insomnia—Ritonavir—acquired immunodeficiency syndrome	7.58e-05	0.00151	CcSEcCtD
Carfilzomib—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	7.53e-05	0.00151	CcSEcCtD
Carfilzomib—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	7.48e-05	0.0015	CcSEcCtD
Carfilzomib—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	7.47e-05	0.00149	CcSEcCtD
Carfilzomib—Nausea—Nelfinavir—acquired immunodeficiency syndrome	7.39e-05	0.00148	CcSEcCtD
Carfilzomib—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	7.37e-05	0.00147	CcSEcCtD
Carfilzomib—Nausea—Stavudine—acquired immunodeficiency syndrome	7.36e-05	0.00147	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	7.35e-05	0.00147	CcSEcCtD
Carfilzomib—Anorexia—Lamivudine—acquired immunodeficiency syndrome	7.33e-05	0.00147	CcSEcCtD
Carfilzomib—Insomnia—Saquinavir—acquired immunodeficiency syndrome	7.29e-05	0.00146	CcSEcCtD
Carfilzomib—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	7.28e-05	0.00146	CcSEcCtD
Carfilzomib—Nausea—Abacavir—acquired immunodeficiency syndrome	7.25e-05	0.00145	CcSEcCtD
Carfilzomib—ABCB1—blood—acquired immunodeficiency syndrome	7.24e-05	0.00286	CbGeAlD
Carfilzomib—Fatigue—Ritonavir—acquired immunodeficiency syndrome	7.22e-05	0.00144	CcSEcCtD
Carfilzomib—Asthenia—Indinavir—acquired immunodeficiency syndrome	7.19e-05	0.00144	CcSEcCtD
Carfilzomib—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	7.19e-05	0.00144	CcSEcCtD
Carfilzomib—Pain—Ritonavir—acquired immunodeficiency syndrome	7.16e-05	0.00143	CcSEcCtD
Carfilzomib—Constipation—Ritonavir—acquired immunodeficiency syndrome	7.16e-05	0.00143	CcSEcCtD
Carfilzomib—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	7.16e-05	0.00143	CcSEcCtD
Carfilzomib—Dizziness—Zidovudine—acquired immunodeficiency syndrome	7.12e-05	0.00142	CcSEcCtD
Carfilzomib—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	7.01e-05	0.0014	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	7.01e-05	0.0014	CcSEcCtD
Carfilzomib—ABCB1—bone marrow—acquired immunodeficiency syndrome	7.01e-05	0.00277	CbGeAlD
Carfilzomib—ABCB1—spinal cord—acquired immunodeficiency syndrome	6.98e-05	0.00275	CbGeAlD
Carfilzomib—Insomnia—Lamivudine—acquired immunodeficiency syndrome	6.96e-05	0.00139	CcSEcCtD
Carfilzomib—Fatigue—Saquinavir—acquired immunodeficiency syndrome	6.95e-05	0.00139	CcSEcCtD
Carfilzomib—Constipation—Saquinavir—acquired immunodeficiency syndrome	6.89e-05	0.00138	CcSEcCtD
Carfilzomib—Pain—Saquinavir—acquired immunodeficiency syndrome	6.89e-05	0.00138	CcSEcCtD
Carfilzomib—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	6.86e-05	0.00137	CcSEcCtD
Carfilzomib—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	6.86e-05	0.00137	CcSEcCtD
Carfilzomib—Vomiting—Zidovudine—acquired immunodeficiency syndrome	6.85e-05	0.00137	CcSEcCtD
Carfilzomib—Asthenia—Efavirenz—acquired immunodeficiency syndrome	6.79e-05	0.00136	CcSEcCtD
Carfilzomib—Headache—Zidovudine—acquired immunodeficiency syndrome	6.75e-05	0.00135	CcSEcCtD
Carfilzomib—ABCB1—vagina—acquired immunodeficiency syndrome	6.71e-05	0.00265	CbGeAlD
Carfilzomib—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	6.69e-05	0.00134	CcSEcCtD
Carfilzomib—Fatigue—Lamivudine—acquired immunodeficiency syndrome	6.63e-05	0.00133	CcSEcCtD
Carfilzomib—Dizziness—Indinavir—acquired immunodeficiency syndrome	6.63e-05	0.00132	CcSEcCtD
Carfilzomib—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	6.62e-05	0.00132	CcSEcCtD
Carfilzomib—Pain—Lamivudine—acquired immunodeficiency syndrome	6.58e-05	0.00131	CcSEcCtD
Carfilzomib—Constipation—Lamivudine—acquired immunodeficiency syndrome	6.58e-05	0.00131	CcSEcCtD
Carfilzomib—Asthenia—Delavirdine—acquired immunodeficiency syndrome	6.5e-05	0.0013	CcSEcCtD
Carfilzomib—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	6.48e-05	0.00129	CcSEcCtD
Carfilzomib—Nausea—Zidovudine—acquired immunodeficiency syndrome	6.4e-05	0.00128	CcSEcCtD
Carfilzomib—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	6.37e-05	0.00127	CcSEcCtD
Carfilzomib—Vomiting—Indinavir—acquired immunodeficiency syndrome	6.37e-05	0.00127	CcSEcCtD
Carfilzomib—ABCB1—lung—acquired immunodeficiency syndrome	6.35e-05	0.00251	CbGeAlD
Carfilzomib—Headache—Indinavir—acquired immunodeficiency syndrome	6.28e-05	0.00125	CcSEcCtD
Carfilzomib—Dizziness—Efavirenz—acquired immunodeficiency syndrome	6.26e-05	0.00125	CcSEcCtD
Carfilzomib—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	6.2e-05	0.00124	CcSEcCtD
Carfilzomib—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	6.08e-05	0.00122	CcSEcCtD
Carfilzomib—Vomiting—Efavirenz—acquired immunodeficiency syndrome	6.02e-05	0.0012	CcSEcCtD
Carfilzomib—Asthenia—Ritonavir—acquired immunodeficiency syndrome	6.01e-05	0.0012	CcSEcCtD
Carfilzomib—Dizziness—Delavirdine—acquired immunodeficiency syndrome	5.99e-05	0.0012	CcSEcCtD
Carfilzomib—Nausea—Indinavir—acquired immunodeficiency syndrome	5.95e-05	0.00119	CcSEcCtD
Carfilzomib—Headache—Efavirenz—acquired immunodeficiency syndrome	5.93e-05	0.00119	CcSEcCtD
Carfilzomib—ABCB1—nervous system—acquired immunodeficiency syndrome	5.88e-05	0.00232	CbGeAlD
Carfilzomib—Asthenia—Saquinavir—acquired immunodeficiency syndrome	5.78e-05	0.00116	CcSEcCtD
Carfilzomib—Vomiting—Delavirdine—acquired immunodeficiency syndrome	5.76e-05	0.00115	CcSEcCtD
Carfilzomib—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	5.73e-05	0.00115	CcSEcCtD
Carfilzomib—Headache—Delavirdine—acquired immunodeficiency syndrome	5.67e-05	0.00113	CcSEcCtD
Carfilzomib—ABCB1—central nervous system—acquired immunodeficiency syndrome	5.66e-05	0.00223	CbGeAlD
Carfilzomib—Nausea—Efavirenz—acquired immunodeficiency syndrome	5.62e-05	0.00112	CcSEcCtD
Carfilzomib—Dizziness—Ritonavir—acquired immunodeficiency syndrome	5.54e-05	0.00111	CcSEcCtD
Carfilzomib—Asthenia—Lamivudine—acquired immunodeficiency syndrome	5.52e-05	0.0011	CcSEcCtD
Carfilzomib—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	5.52e-05	0.0011	CcSEcCtD
Carfilzomib—Nausea—Delavirdine—acquired immunodeficiency syndrome	5.38e-05	0.00108	CcSEcCtD
Carfilzomib—Dizziness—Saquinavir—acquired immunodeficiency syndrome	5.33e-05	0.00107	CcSEcCtD
Carfilzomib—Vomiting—Ritonavir—acquired immunodeficiency syndrome	5.33e-05	0.00106	CcSEcCtD
Carfilzomib—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	5.26e-05	0.00105	CcSEcCtD
Carfilzomib—Headache—Ritonavir—acquired immunodeficiency syndrome	5.25e-05	0.00105	CcSEcCtD
Carfilzomib—Vomiting—Saquinavir—acquired immunodeficiency syndrome	5.13e-05	0.00102	CcSEcCtD
Carfilzomib—Dizziness—Lamivudine—acquired immunodeficiency syndrome	5.09e-05	0.00102	CcSEcCtD
Carfilzomib—Headache—Saquinavir—acquired immunodeficiency syndrome	5.05e-05	0.00101	CcSEcCtD
Carfilzomib—Nausea—Ritonavir—acquired immunodeficiency syndrome	4.98e-05	0.000995	CcSEcCtD
Carfilzomib—Vomiting—Lamivudine—acquired immunodeficiency syndrome	4.89e-05	0.000978	CcSEcCtD
Carfilzomib—Headache—Lamivudine—acquired immunodeficiency syndrome	4.82e-05	0.000963	CcSEcCtD
Carfilzomib—Nausea—Saquinavir—acquired immunodeficiency syndrome	4.79e-05	0.000957	CcSEcCtD
Carfilzomib—Nausea—Lamivudine—acquired immunodeficiency syndrome	4.57e-05	0.000913	CcSEcCtD
Carfilzomib—ABCB1—brain—acquired immunodeficiency syndrome	4.49e-05	0.00177	CbGeAlD
Carfilzomib—ABCB1—lymph node—acquired immunodeficiency syndrome	4.34e-05	0.00171	CbGeAlD
Carfilzomib—PSMB5—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	4.28e-05	0.00173	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	4.28e-05	0.00173	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	4.28e-05	0.00173	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	4.26e-05	0.00172	CbGpPWpGaD
Carfilzomib—PSMB8—Interferon Signaling—IFNG—acquired immunodeficiency syndrome	4.25e-05	0.00172	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	4.24e-05	0.00172	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	4.22e-05	0.00171	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—CCNT1—acquired immunodeficiency syndrome	3.99e-05	0.00161	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—CCNT1—acquired immunodeficiency syndrome	3.99e-05	0.00161	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—CCNT1—acquired immunodeficiency syndrome	3.99e-05	0.00161	CbGpPWpGaD
Carfilzomib—ABCB1—Allograft Rejection—IL10—acquired immunodeficiency syndrome	3.96e-05	0.0016	CbGpPWpGaD
Carfilzomib—ABCB1—Allograft Rejection—CD40LG—acquired immunodeficiency syndrome	3.96e-05	0.0016	CbGpPWpGaD
Carfilzomib—PSMB10—Apoptosis—TNF—acquired immunodeficiency syndrome	3.94e-05	0.00159	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—CCNT1—acquired immunodeficiency syndrome	3.93e-05	0.00159	CbGpPWpGaD
Carfilzomib—PSMB9—Apoptosis—TNF—acquired immunodeficiency syndrome	3.92e-05	0.00159	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—AGPS—acquired immunodeficiency syndrome	3.88e-05	0.00157	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—AGPS—acquired immunodeficiency syndrome	3.88e-05	0.00157	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—AGPS—acquired immunodeficiency syndrome	3.88e-05	0.00157	CbGpPWpGaD
Carfilzomib—ABCB1—Allograft Rejection—IL4—acquired immunodeficiency syndrome	3.85e-05	0.00156	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—AGPS—acquired immunodeficiency syndrome	3.83e-05	0.00155	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—MBL2—acquired immunodeficiency syndrome	3.77e-05	0.00153	CbGpPWpGaD
Carfilzomib—ABCB1—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	3.77e-05	0.00152	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—MBL2—acquired immunodeficiency syndrome	3.76e-05	0.00152	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—CCNT1—acquired immunodeficiency syndrome	3.71e-05	0.0015	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—CCNT1—acquired immunodeficiency syndrome	3.71e-05	0.0015	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—CCNT1—acquired immunodeficiency syndrome	3.71e-05	0.0015	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—CCNT1—acquired immunodeficiency syndrome	3.65e-05	0.00148	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—ACTG1—acquired immunodeficiency syndrome	3.48e-05	0.00141	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—ACTG1—acquired immunodeficiency syndrome	3.48e-05	0.00141	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—ACTG1—acquired immunodeficiency syndrome	3.48e-05	0.00141	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	3.48e-05	0.00141	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	3.46e-05	0.0014	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	3.44e-05	0.00139	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—ACTG1—acquired immunodeficiency syndrome	3.43e-05	0.00139	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.42e-05	0.00138	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.42e-05	0.00138	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	3.42e-05	0.00138	CbGpPWpGaD
Carfilzomib—PSMB2—HIV Infection—CD4—acquired immunodeficiency syndrome	3.42e-05	0.00138	CbGpPWpGaD
Carfilzomib—PSMB5—HIV Infection—CD4—acquired immunodeficiency syndrome	3.42e-05	0.00138	CbGpPWpGaD
Carfilzomib—PSMB1—HIV Infection—CD4—acquired immunodeficiency syndrome	3.42e-05	0.00138	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.41e-05	0.00138	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.41e-05	0.00138	CbGpPWpGaD
Carfilzomib—PSMB8—HIV Infection—CD4—acquired immunodeficiency syndrome	3.37e-05	0.00136	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	3.31e-05	0.00134	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	3.29e-05	0.00133	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	3.23e-05	0.00131	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	3.23e-05	0.00131	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	3.23e-05	0.00131	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	3.19e-05	0.00129	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.1e-05	0.00125	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.08e-05	0.00125	CbGpPWpGaD
Carfilzomib—PSMB2—Apoptosis—TNF—acquired immunodeficiency syndrome	2.99e-05	0.00121	CbGpPWpGaD
Carfilzomib—PSMB1—Apoptosis—TNF—acquired immunodeficiency syndrome	2.99e-05	0.00121	CbGpPWpGaD
Carfilzomib—PSMB5—Apoptosis—TNF—acquired immunodeficiency syndrome	2.99e-05	0.00121	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—CCR2—acquired immunodeficiency syndrome	2.96e-05	0.0012	CbGpPWpGaD
Carfilzomib—PSMB8—Apoptosis—TNF—acquired immunodeficiency syndrome	2.95e-05	0.00119	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—CCR2—acquired immunodeficiency syndrome	2.94e-05	0.00119	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—MBL2—acquired immunodeficiency syndrome	2.86e-05	0.00116	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—MBL2—acquired immunodeficiency syndrome	2.86e-05	0.00116	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—MBL2—acquired immunodeficiency syndrome	2.86e-05	0.00116	CbGpPWpGaD
Carfilzomib—PSMB8—Cytokine Signaling in Immune system—IFNG—acquired immunodeficiency syndrome	2.84e-05	0.00115	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—MBL2—acquired immunodeficiency syndrome	2.82e-05	0.00114	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IFNA1—acquired immunodeficiency syndrome	2.66e-05	0.00108	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IFNA1—acquired immunodeficiency syndrome	2.65e-05	0.00107	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	2.63e-05	0.00106	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	2.63e-05	0.00106	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	2.63e-05	0.00106	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	2.6e-05	0.00105	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	2.6e-05	0.00105	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	2.6e-05	0.00105	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	2.6e-05	0.00105	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.59e-05	0.00105	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.59e-05	0.00105	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.59e-05	0.00105	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.59e-05	0.00105	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.59e-05	0.00105	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.59e-05	0.00105	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—CD79A—acquired immunodeficiency syndrome	2.59e-05	0.00105	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—CD79A—acquired immunodeficiency syndrome	2.57e-05	0.00104	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—CXCR4—acquired immunodeficiency syndrome	2.57e-05	0.00104	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	2.57e-05	0.00104	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.56e-05	0.00103	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.56e-05	0.00103	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—CXCR4—acquired immunodeficiency syndrome	2.56e-05	0.00103	CbGpPWpGaD
Carfilzomib—PSMB8—Cytokine Signaling in Immune system—IL2—acquired immunodeficiency syndrome	2.52e-05	0.00102	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	2.51e-05	0.00101	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	2.51e-05	0.00101	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	2.51e-05	0.00101	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	2.47e-05	0.000999	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.35e-05	0.000949	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.35e-05	0.000949	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.35e-05	0.000949	CbGpPWpGaD
Carfilzomib—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	2.33e-05	0.000942	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.31e-05	0.000935	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CCR2—acquired immunodeficiency syndrome	2.24e-05	0.000907	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CCR2—acquired immunodeficiency syndrome	2.24e-05	0.000907	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CCR2—acquired immunodeficiency syndrome	2.24e-05	0.000907	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CCR2—acquired immunodeficiency syndrome	2.21e-05	0.000894	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.12e-05	0.000855	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—CD40LG—acquired immunodeficiency syndrome	2.11e-05	0.000852	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.11e-05	0.000851	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—CD40LG—acquired immunodeficiency syndrome	2.1e-05	0.000848	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—CSF2—acquired immunodeficiency syndrome	2.08e-05	0.000843	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—CD8A—acquired immunodeficiency syndrome	2.08e-05	0.000843	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—CSF2—acquired immunodeficiency syndrome	2.07e-05	0.000839	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—CD8A—acquired immunodeficiency syndrome	2.07e-05	0.000839	CbGpPWpGaD
Carfilzomib—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	2.07e-05	0.000837	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IFNA1—acquired immunodeficiency syndrome	2.02e-05	0.000816	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IFNA1—acquired immunodeficiency syndrome	2.02e-05	0.000816	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IFNA1—acquired immunodeficiency syndrome	2.02e-05	0.000816	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—HLA-B—acquired immunodeficiency syndrome	2.01e-05	0.000811	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—HLA-B—acquired immunodeficiency syndrome	2e-05	0.000807	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IFNA1—acquired immunodeficiency syndrome	1.99e-05	0.000805	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.97e-05	0.000798	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.96e-05	0.000794	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CD79A—acquired immunodeficiency syndrome	1.96e-05	0.000792	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CD79A—acquired immunodeficiency syndrome	1.96e-05	0.000792	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CD79A—acquired immunodeficiency syndrome	1.96e-05	0.000792	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—CXCR4—acquired immunodeficiency syndrome	1.95e-05	0.000787	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—CXCR4—acquired immunodeficiency syndrome	1.95e-05	0.000787	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—CXCR4—acquired immunodeficiency syndrome	1.95e-05	0.000787	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CD79A—acquired immunodeficiency syndrome	1.93e-05	0.000781	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—CXCR4—acquired immunodeficiency syndrome	1.92e-05	0.000776	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.91e-05	0.000773	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.9e-05	0.00077	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.8e-05	0.000727	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.8e-05	0.000727	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.79e-05	0.000724	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.79e-05	0.000724	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—CCR5—acquired immunodeficiency syndrome	1.76e-05	0.000712	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—CCR5—acquired immunodeficiency syndrome	1.75e-05	0.000708	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.6e-05	0.000648	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.6e-05	0.000648	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.6e-05	0.000648	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CD40LG—acquired immunodeficiency syndrome	1.6e-05	0.000646	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CD40LG—acquired immunodeficiency syndrome	1.6e-05	0.000646	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CD40LG—acquired immunodeficiency syndrome	1.6e-05	0.000646	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.58e-05	0.000639	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CD8A—acquired immunodeficiency syndrome	1.58e-05	0.000639	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CD8A—acquired immunodeficiency syndrome	1.58e-05	0.000639	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CSF2—acquired immunodeficiency syndrome	1.58e-05	0.000639	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CSF2—acquired immunodeficiency syndrome	1.58e-05	0.000639	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CD8A—acquired immunodeficiency syndrome	1.58e-05	0.000639	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CSF2—acquired immunodeficiency syndrome	1.58e-05	0.000639	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CD40LG—acquired immunodeficiency syndrome	1.58e-05	0.000637	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CD8A—acquired immunodeficiency syndrome	1.56e-05	0.00063	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CSF2—acquired immunodeficiency syndrome	1.56e-05	0.00063	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—HLA-B—acquired immunodeficiency syndrome	1.52e-05	0.000614	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—HLA-B—acquired immunodeficiency syndrome	1.52e-05	0.000614	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—HLA-B—acquired immunodeficiency syndrome	1.52e-05	0.000614	CbGpPWpGaD
Carfilzomib—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	1.51e-05	0.000609	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—HLA-B—acquired immunodeficiency syndrome	1.5e-05	0.000606	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.5e-05	0.000605	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.5e-05	0.000605	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.5e-05	0.000605	CbGpPWpGaD
Carfilzomib—PSMB8—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	1.48e-05	0.000599	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.47e-05	0.000596	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.45e-05	0.000586	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.45e-05	0.000586	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.45e-05	0.000586	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.43e-05	0.000578	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.37e-05	0.000553	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.36e-05	0.000551	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.36e-05	0.000551	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.36e-05	0.000551	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.36e-05	0.000551	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.36e-05	0.000551	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.36e-05	0.000551	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.36e-05	0.000551	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.35e-05	0.000545	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.34e-05	0.000543	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.34e-05	0.000543	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	1.34e-05	0.000543	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.34e-05	0.000542	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—CCR5—acquired immunodeficiency syndrome	1.33e-05	0.000539	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—CCR5—acquired immunodeficiency syndrome	1.33e-05	0.000539	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—CCR5—acquired immunodeficiency syndrome	1.33e-05	0.000539	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—CCR5—acquired immunodeficiency syndrome	1.32e-05	0.000532	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IFNG—acquired immunodeficiency syndrome	1.24e-05	0.000501	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IFNG—acquired immunodeficiency syndrome	1.23e-05	0.000499	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.23e-05	0.000498	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.23e-05	0.000496	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—CD4—acquired immunodeficiency syndrome	1.2e-05	0.000484	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—CD4—acquired immunodeficiency syndrome	1.19e-05	0.000482	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	1.14e-05	0.000462	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—CD4—acquired immunodeficiency syndrome	1.11e-05	0.000447	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IL2—acquired immunodeficiency syndrome	1.1e-05	0.000445	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—CD4—acquired immunodeficiency syndrome	1.1e-05	0.000445	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IL2—acquired immunodeficiency syndrome	1.1e-05	0.000443	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—ALB—acquired immunodeficiency syndrome	1.05e-05	0.000425	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—ALB—acquired immunodeficiency syndrome	1.05e-05	0.000423	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.04e-05	0.000419	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.04e-05	0.000419	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.04e-05	0.000419	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.02e-05	0.000413	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.02e-05	0.000413	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.02e-05	0.000413	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.02e-05	0.000413	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.01e-05	0.000407	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IFNG—acquired immunodeficiency syndrome	9.39e-06	0.00038	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IFNG—acquired immunodeficiency syndrome	9.39e-06	0.00038	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IFNG—acquired immunodeficiency syndrome	9.39e-06	0.00038	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.34e-06	0.000378	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.34e-06	0.000378	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.34e-06	0.000378	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IFNG—acquired immunodeficiency syndrome	9.26e-06	0.000374	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.21e-06	0.000372	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CD4—acquired immunodeficiency syndrome	9.07e-06	0.000367	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CD4—acquired immunodeficiency syndrome	9.07e-06	0.000367	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CD4—acquired immunodeficiency syndrome	9.07e-06	0.000367	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CD4—acquired immunodeficiency syndrome	8.95e-06	0.000362	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—CD4—acquired immunodeficiency syndrome	8.38e-06	0.000339	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—CD4—acquired immunodeficiency syndrome	8.38e-06	0.000339	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—CD4—acquired immunodeficiency syndrome	8.38e-06	0.000339	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL2—acquired immunodeficiency syndrome	8.35e-06	0.000338	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL2—acquired immunodeficiency syndrome	8.35e-06	0.000338	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL2—acquired immunodeficiency syndrome	8.35e-06	0.000338	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—CD4—acquired immunodeficiency syndrome	8.26e-06	0.000334	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL2—acquired immunodeficiency syndrome	8.23e-06	0.000333	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—ALB—acquired immunodeficiency syndrome	7.96e-06	0.000322	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—ALB—acquired immunodeficiency syndrome	7.96e-06	0.000322	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—ALB—acquired immunodeficiency syndrome	7.96e-06	0.000322	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—ALB—acquired immunodeficiency syndrome	7.85e-06	0.000317	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	7.44e-06	0.000301	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.12e-06	0.000288	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.09e-06	0.000287	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IL6—acquired immunodeficiency syndrome	6.47e-06	0.000262	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IL6—acquired immunodeficiency syndrome	6.44e-06	0.000261	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—IL6—acquired immunodeficiency syndrome	5.98e-06	0.000242	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—IL6—acquired immunodeficiency syndrome	5.95e-06	0.000241	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.4e-06	0.000218	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.4e-06	0.000218	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.4e-06	0.000218	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.32e-06	0.000215	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	5e-06	0.000202	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL6—acquired immunodeficiency syndrome	4.91e-06	0.000198	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL6—acquired immunodeficiency syndrome	4.91e-06	0.000198	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL6—acquired immunodeficiency syndrome	4.91e-06	0.000198	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL6—acquired immunodeficiency syndrome	4.84e-06	0.000196	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—IL6—acquired immunodeficiency syndrome	4.53e-06	0.000183	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—IL6—acquired immunodeficiency syndrome	4.53e-06	0.000183	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—IL6—acquired immunodeficiency syndrome	4.53e-06	0.000183	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—IL6—acquired immunodeficiency syndrome	4.47e-06	0.000181	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.19e-06	0.000169	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.17e-06	0.000168	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.17e-06	0.000128	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.17e-06	0.000128	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.17e-06	0.000128	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.13e-06	0.000126	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	2.34e-06	9.47e-05	CbGpPWpGaD
